CTOs on the Move

Culture Biosciences

www.culturebiosciences.com

 
Culture Biosciences develops automated bioreactor infrastructures and runs it as a service for biotech companies.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Culture Biosciences raised $15M on 03/04/2020

Similar Companies

Janpix

Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.

MARATHONLS

Marathon Life Sciences Laboratory Solutions at the Speed of Science Learn more Our Lab Supplies Line Cell Strainer Download Catalogadd to cart Tissue Culture Plates Download Catalog 15/50mL Centrifuge Tubes Download Catalog Petri Dishes Download Catalo...

MicroDose Therapeutx

MicroDose Therapeutx is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

89 North

89 North is a Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boundless Bio

Boundless Bio, a San Diego based company backed by ARCH Venture Partners, is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.